Roche: positive CHMP opinion for Vabysmo in OVR
This positive recommendation is based on two Phase 3 studies which, in addition to robust retinal drying with Vabysmo, showed early and durable improvements in vision, which are not inferior to aflibercept.
A final decision is expected from the European Commission in the near future. If approved, Vabysmo would be the first and only bispecific antibody treatment available for nearly a million people with RVO in the EU.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction